{"id":43931,"date":"2026-04-03T11:18:28","date_gmt":"2026-04-03T11:18:28","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/43931\/"},"modified":"2026-04-03T11:18:28","modified_gmt":"2026-04-03T11:18:28","slug":"novartis-to-buy-allergy-drug-developer-excellergy-for-up-to-2-billion","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/43931\/","title":{"rendered":"Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion"},"content":{"rendered":"<p data-type=\"paragraph\" data=\"[object Object]\" class=\"css-1akm6h5-Paragraph e1e4oisd0\"><a data-type=\"company\" href=\"https:\/\/www.wsj.com\/market-data\/quotes\/CH\/XSWX\/NOVN\" target=\"_blank\" class=\"ekxajjj0 css-i0lbhy-OverridedLink\" rel=\"nofollow noopener\">Novartis<\/a> <a href=\"https:\/\/www.wsj.com\/market-data\/quotes\/CH\/XSWX\/NOVN\" class=\"css-1p1beha-ChicletStyle e1vl9ktx2\" rel=\"nofollow noopener\" target=\"_blank\">NOVN 1.69%increase; green up pointing triangle<\/a> said it agreed to buy biotech company Excellergy for up to $2 billion, adding a new approach to treat allergic diseases to its immunology pipeline.<\/p>\n<p data-type=\"paragraph\" data=\"[object Object]\" class=\"css-1akm6h5-Paragraph e1e4oisd0\">The Swiss pharmaceutical company said Friday that the deal for privately held Excellergy brings in a drug candidate in early-stage trials with potential to complement its existing allergy portfolio.<\/p>\n<p class=\"css-16aepit e1jdulti0\">Copyright \u00a92026 Dow Jones &amp; Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis NOVN 1.69%increase; green up pointing triangle said it agreed to buy biotech company Excellergy for up to&hellip;\n","protected":false},"author":2,"featured_media":43932,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[1766,6271,6270,25355,25364,6277,12822,25359,6274,1126,6272,6273,2115,6275,2783,1002,4128,25348,6288,25353,25352,1831,25360,228,25357,1767,25362,25354,25361,25349,6263,206,25358,6269,3708,337,10728,25356,1138,25351,338,25350,14716,25347,25363,12081,6287,6278,6279],"class_list":["post-43931","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-acquisitions","tag-acquisitions-mergers","tag-acquisitions-mergers-shareholdings","tag-allergies","tag-allergy-treatments","tag-ce-industry-news-filter","tag-cancer-drugs","tag-chnovn","tag-content-types","tag-corporate","tag-corporate-actions","tag-corporate-industrial-news","tag-development","tag-factiva-filters","tag-general-news","tag-health","tag-healthcare","tag-healthcare-life-sciences","tag-industrial-news","tag-industrial-property-rights","tag-intellectual-property-rights","tag-life-sciences","tag-linkendrnrealtime-linkedarticle-dnco20260327002828","tag-manufacturing","tag-medical-conditions","tag-mergers","tag-new-product","tag-new-product-service-testing","tag-new-products","tag-new-products-services","tag-newsplus","tag-novartis","tag-novn-eb","tag-ownership-changes","tag-patents","tag-pharmaceuticals","tag-political","tag-political-general-news","tag-products","tag-products-services","tag-research","tag-research-development","tag-respiratory","tag-respiratory-allergy-treatments","tag-service-testing","tag-services","tag-shareholdings","tag-synd","tag-wsj-pro-wsj-com"],"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/43931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=43931"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/43931\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/43932"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=43931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=43931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=43931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}